Person:
ERDOĞAN, EZGİ BAŞAK

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
EZGİ BAŞAK
Last Name
ERDOĞAN
Name
Email Address
Birth Date

Filters

2020 - 20224
Reset filters

Settings

Start date: 2020 × End date: 2022 ×

Search Results

Now showing 1 - 4 of 4
  • No Thumbnail Available
    PublicationMetadata only
  • Thumbnail Image
    PublicationOpen Access
    Investigation of Added Value of Imaging Performed in a Prone Position to Standard 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Staging in Patients with Breast Cancer
    (2022-02-02T00:00:00Z) Erdoğan, Ezgi Başak; Aydın, MEHMET; ERDOĞAN, EZGİ BAŞAK; AYDIN, MEHMET
    Objectives: To investigate whether additional imaging in a prone position has any value to the supine whole-body 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) images by comparing the visual and quantitative data about a local disease in the breast and axilla for the initial staging of breast cancer (BC). Methods: In this study, a total of 91 female patients with the BC were studied. Both the supine and prone images were examined based on the axial diameter, number and location of the primary tumor, local invasion signs of the tumor, the number of axillary lymph nodes with a suspected metastasis, metabolic parameters of the primary tumor and axillary lymph nodes, and registration artifacts of the PET and CT images were evaluated individually. These findings were compared with the histopathological data obtained after a surgery. Results: In the evaluation of a supine and prone imaging, tumor diameter and metabolic tumor volume (MTV) values of the breast lesions were greater in the supine position than in the prone position. However, there was no significant difference found between the other metabolic parameters of a primary tumor and axilla in both positions. In the supine and prone images, accuracy for skin involvement was 84% and 91.3%, respectively. Conclusion: In our study, we observed that, obtaining additional images in the prone position does not significantly benefit the evaluation of a local disease. The average values of the primary tumor diameter and MTV in the prone position appear to be smaller than the one in the supine position. However, the prone imaging in the patients with a newly diagnosed BC may be beneficial in selected patients and may contribute to preventing the false-positive results especially in patients with a suspected skin involvement. Keywords: 18F-fluorodeoxyglucose (18F-FDG); Breast cancer; positron emission tomography/computed tomography (PET/CT); prone position.
  • No Thumbnail Available
    PublicationMetadata only
    Can PET-CT replace bone marrow biopsy for lymphoma staging? Retrospective analysis of 198 Hodgkin and non-Hodgkin lymphoma cases
    (2021-06-01T00:00:00Z) Güler, Beril; Adilli, Adila; Uysal, Ömer; GÜLER, BERIL; ERDOĞAN, EZGİ BAŞAK; UYSAL, ÖMER
    Aim: Lymphoma staging is important from the prognostic and therapeutic point of view and bone marrow biopsy performed for this purpose makes up a large part of current hematopathology practice. PET-CT is the currently preferred method to evaluate bone marrow involvement by lymphoproliferative disorders as it is non-invasive and practical. The aim of this study was to compare trephine biopsy and PET-CT results as regards determining bone marrow involvement in various lymphoma subtypes. Materials and Methods: A total number of 198 bone marrow biopsies and 185 PET-CT images of cases consisting of various lymphoma subtypes were included in the study. The results of both methods evaluated for bone marrow infiltration were grouped as positive, negative, and suspicious to compare consistency. Statistical agreement was calculated with the kappa coefficient. The sensitivity, specificity, and the positive and negative predictive values were calculated as the diagnostic test measures. Results: Twenty-six cases (15.8%) had lymphoma involvement in trephine biopsies and 36 cases (21.2%) had positive findings for lymphoma involvement of the bone marrow on PET-CT. The two methods had weak statistical agreement (κ= 0.21). Biopsy and PETCT results were similar in 132 cases (71.20%). PET-CT showed false negative results in 11 cases in which infiltration was observed with biopsy. Twenty-six cases that were negative for lymphoma involvement on biopsy were accepted as positive on PET-CT and 16 of these cases were classical Hodgkin-s lymphoma. One case with suspicious bone marrow biopsy was positive on PET-CT, while four cases with suspicious PET-CT results were positive on biopsy. Conclusion: The results showed that both of the methods have advantages and disadvantages as regards lymphoma staging. However, histopathology is globally accepted as the gold standard for a definite diagnosis. We believe that the complementary use of the two methods is more beneficial for correct guidance during clinical practice.
  • Thumbnail Image
    PublicationOpen Access
    The Role of Post-treatment FDG-PET/CT Scanning after the First-line Chemotherapy in Predicting Prognosis in Patients with Hodgkin Disease and High-grade Non-Hodgkin Lymphoma: A Comparative Study with Clinical Prognostic Risk Scoring Data
    (2022-06-01T00:00:00Z) ERDOĞAN, EZGİ BAŞAK; Guner, Sebnem; SÖNMEZOĞLU, KERİM; ERDOĞAN, EZGİ BAŞAK
    Objective: We aimed to evaluate the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) performed after the first-line therapy in predicting prognosis of lymphomas and compare the results with the pretreatment prognostic risk scoring (PRS) indices. Methods: One hundred three patients with histopathologically confirmed Hodgkin (HD) and high-grade non-Hodgkin lymphoma (NHL) were included in the study. All patients received FDG-PET/CT imaging after the end of primary treatment. After intraveneus application of FDG, whole body PET/CT from the upper thigh to the vertex was performed. Results: The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of post-treatment FDG-PET/CT imaging in predicting remission status were 73.6%, 91.6%, 88%, 66.6%, and 94.0%, respectively. Those values were 63.0%, 62.0%, 62.0%, 27%, and 88.0% respectively, for pretreatment clinical risk scoring (p<0.001). Among the patients with positive PET scans after ending of the first-line therapy, 71.4% of those with only single lymph node station involvement stayed in remission, whereas 12.5% of the patients who had involvement of multiple lymph node stations and 16.7% of the patients who had extranodal disease could sustain in remission (p<0.05). Conclusion: We found that FDG-PET performed after first-line therapy was superior to clinical PRS systems in predicting prognosis of HD and NHL disease as conclusions. Although it was more successful to predict patients who would stay in remission with its high NPV, FDG-PET/CT imaging had a lower PPV due to false positive results. However, persistent FDG uptake in multinodal lymphatic stations and/or in extranodal sites on the post-therapy PET/CT scanning was more suggestive in predicting risk for recurrence.